skisci
- 8
- 0
Are there any methods to "knockout" genes in-vivo? For example, the HOXB7 gene (http://www.physorg.com/news/2010-12-hoxb7-gene-tamoxifen-resistance.html) in cancer patents.
The discussion revolves around methods for in-vivo gene knockout, specifically focusing on techniques such as siRNA and the Cre/LoxP system. Participants explore the potential applications and challenges associated with these methods in the context of gene therapy and cancer treatment.
Participants express various viewpoints on the effectiveness and applicability of different gene knockout methods, with no clear consensus reached on the best approach or the current state of research in this area.
Limitations include the dependence on specific genetic modifications for certain methods, the potential for incomplete gene silencing, and the challenges of applying laboratory techniques to living human patients.
This discussion may be of interest to researchers and practitioners in genetics, molecular biology, and gene therapy, as well as those exploring innovative approaches to cancer treatment.
skisci said:Are there any methods to "knockout" genes in-vivo? For example, the HOXB7 gene (http://www.physorg.com/news/2010-12-hoxb7-gene-tamoxifen-resistance.html) in cancer patents.
skisci said:Thanks.
Is there any leakage from unbinded mRNA fragments that then do get translated into proteins?
Could one tailor a virus to splice the siRNA DNA into a target cell so the siRNA could be manufactured inter-cellularly? (I.E. Lytic cycle without the virus parts)
skisci said:siRNA, from my understanding, can interfere with gene expression post-transcriptionally and therefore can be used on an unprimed (if you will) genome. I feel this route has more promise for clinical applications. A few questions.
Andy Resnick said:Gene therapy has been pursued for more than a decade, with not much success:
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetherapy.shtml
I'm (somewhat) familiar with the case of Jesse Gelsinger. He had a variant of cystic fibrosis, which was identified as a candidate disease for gene therapy since the lung is an easy organ to target (inhale the carrier).
People are still trying various approaches with some success, but progress is very slow.
skisci said:Is there any leakage from unbinded mRNA fragments that then do get translated into proteins?
Could one tailor a virus to splice the siRNA DNA into a target cell so the siRNA could be manufactured inter-cellularly? (I.E. Lytic cycle without the virus parts)